Phosphate wasting disorders in adults.
- Marcucci G Metabolic Bone Diseases Unit, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.
- Masi L Metabolic Bone Diseases Unit, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.
- Ferrarì S Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
- Haffner D Department of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Hannover, Germany.
- Javaid MK Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
- Kamenický P Service d'Endocrinologie et des Maladies de la Reproduction, Centre de référence des Maladies Rares du métabolisme du calcium et du phosphore, Hopital de Bicêtre - AP-HP, 94275, Le Kremlin-Bicêtre, France.
- Reginster JY Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.
- Rizzoli R Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
- Brandi ML Metabolic Bone Diseases Unit, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy. marialuisa.brandi@unifi.it.
- 2018-07-18
Published in:
- Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. - 2018
FGF-23
Hypophosphatemia
Osteomalacia
Phosphate wasting disorders
Rickets
Treatment
Fibroblast Growth Factors
Homeostasis
Humans
Hypophosphatemia
Intestinal Absorption
Kidney
Molecular Targeted Therapy
Osteomalacia
Phosphates
English
A cause of hypophosphatemia is phosphate wasting disorders. Knowledge concerning mechanisms involved in phosphate wasting disorders has greatly increased in the last decade by the identification of phosphatonins, among them FGF-23. FGF-23 is a primarily bone derived factor decreasing renal tubular reabsorption of phosphate and the synthesis of calcitriol. Currently, pharmacological treatment of these disorders offers limited efficacy and is potentially associated to gastrointestinal, renal, and parathyroid complications; therefore, efforts have been directed toward newer pharmacological strategies that target the FGF-23 pathway. This review focuses on phosphate metabolism, its main regulators, and phosphate wasting disorders in adults, highlighting the main issues related to diagnosis and current and new potential treatments.
- Language
-
- English
- Open access status
- green
- Identifiers
-
- DOI 10.1007/s00198-018-4618-2
- PMID 30014155
- Persistent URL
- https://sonar.ch/global/documents/232765
Statistics
Document views: 24
File downloads:
- Full-text: 0